» Articles » PMID: 28121339

The Cost of Atrial Fibrillation in Italy: a Five-year Analysis of Healthcare Expenditure in the General Population. From the Italian Survey of Atrial Fibrillation Management (ISAF) Study

Overview
Date 2017 Jan 26
PMID 28121339
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Atrial fibrillation (AF) is a relevant item of expenditure for the National Healthcare systems. The aim of the study was to estimate the annual costs of AF in Italy.

Patients And Methods: The Italian Survey of Atrial Fibrillation Management Study enrolled 6.036 patients with AF among 295.906 subjects representative of the Italian population. Data were collected by 233 General Practitioners (GPs) distributed across Italy. Quantities of resources used during the 5 years preceding the ISAF screening were inferred from the survey data and multiplied by the current Italian unit costs of 2015 in order to estimate the mean per patient annual cumulative cost of AF. Patients were subdivided on the basis of the number of hospitalizations, invasive/non-invasive diagnostic tests and invasive therapeutic procedures in 3 different clinical subsets: "low cost", " medium cost" and "high cost clinical scenario".

Results: The estimated mean costs per patient per year were 613 €, 891 € and 1213 € for the "Low cost", "Medium cost" and "High Cost Clinical Scenario" respectively. Hospitalizations and inpatient interventional procedures accounted for more than 80% of the cumulative annual costs. The mean annual costs among patients pursuing "Rhythm control" strategy was 956 €.

Conclusions: In Italy, the estimated costs of AF per patient per year are lower than those reported in other developed countries and vary widely related to the different characteristics of AF patients. Hospitalizations and interventional procedures are the main drivers of costs. The mean annual cost of AF is mainly influenced by the duration of the period of observation and the patients' characteristics. Measures to reduce hospitalizations are needed.

Citing Articles

Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation....

Walli-Attaei M, Little M, Luengo-Fernandez R, Gray A, Torbica A, Maggioni A Europace. 2024; 26(6).

PMID: 38807488 PMC: 11164571. DOI: 10.1093/europace/euae146.


The prognostic value of quality of life in atrial fibrillation on patient value.

Theunissen L, Van De Pol J, van Steenbergen G, Cremers H, van Veghel D, van der Voort P Health Qual Life Outcomes. 2023; 21(1):33.

PMID: 37016364 PMC: 10074786. DOI: 10.1186/s12955-023-02112-2.


LSD1 in beige adipocytes protects cardiomyocytes against oxygen and glucose deprivation.

Cao Y, Dong Z, Yang D, Wang X Iran J Basic Med Sci. 2023; 26(1):30-36.

PMID: 36594068 PMC: 9790061. DOI: 10.22038/IJBMS.2022.65006.14313.


Atrial Fibrillation and the Risk of Early-Onset Dementia: A Systematic Review and Meta-Analysis.

Giannone M, Filippini T, Whelton P, Chiari A, Vitolo M, Boriani G J Am Heart Assoc. 2022; 11(14):e025653.

PMID: 35861843 PMC: 9707836. DOI: 10.1161/JAHA.122.025653.


Editorial: Atrial Fibrillation: Technology for Diagnosis, Monitoring, and Treatment.

Berenfeld O, Corino V, Loewe A, Martinez J, Rodriguez Matas J Front Physiol. 2022; 13:848096.

PMID: 35283792 PMC: 8905513. DOI: 10.3389/fphys.2022.848096.